Effect Of sodium glucose co-transporter 2 inhibitors on weight reduction in overweight and obese population: A review

Abstract

Obesity is a global health concern and a large percentage of world is affected by it. Lifestyle changes are necessary and several therapy options are available to address it. Sodium glucose cotransporter 2 (SGLT-2) inhibitors show promising results in weight reduction. Although SGLT-2 inhibitors are approved by FDA for treating type 2 diabetes, recent trials have shown their effectiveness in weight loss. In the current study, the co-administration of 300 mg Canagliflozin and 15 mg phentermine has been found to have the highest efficacy, followed by 150 mg Licogliflozin once a day (q.d) and 25 mg Licogliflozin twice a day (b.i.d) which is moderately effective, and lastly 100 mg Canagliflozin once daily (q.d), which is has the lowest efficacy. Based on adverse effects like genital mycotic infection and urinary tract infections, Canagliflozin can be considered as a safe drug. Further clinical trials and post marketing data are required to confirm this finding.